Adrenocorticotropic hormone independent macronodular adrenal hyperplasia due to aberrant receptor expression: Is medical treatment always an option?

Endocrine Practice

Volumn 19, Issue 3, 2013, Pages

  Karapanou, Olga ^a   Vlassopoulou, Barbara ^a   Tzanela, Marinella ^a   Stratigou, Theodora ^a   Tsatlidis, Vassilios ^a   Tsirona, Sofia ^a   Tsagarakis, Stylianos ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CORTICOTROPIN; DEXAMETHASONE; GONADORELIN; HYDROCORTISONE; LEUPRORELIN; LUTEINIZING HORMONE RECEPTOR; OCTREOTIDE; RELEFACT LH RH; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADRENAL HYPERPLASIA; ADRENAL TUMOR; ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA; ADULT; ARTICLE; BLOOD CHEMISTRY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN TEST; CUSHING DISEASE; DEXAMETHASONE SUPPRESSION TEST; DRUG EFFICACY; DRUG RELEASE; FEMALE; FOOD; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; LONG ACTING RELEASE; LOW DOSE DEXAMETHASONE SUPPRESSION TEST; LOW DRUG DOSE; MEAL; MENOPAUSE; NODULAR HYPERPLASIA; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT GAIN;

ADULT; CHORIONIC GONADOTROPIN; CUSHING SYNDROME; FEMALE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; OCTREOTIDE;

EID: 84880108568     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12346.CR     Document Type: Article

References (19)

1. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol(Oxf). 2010;73:1-15.
2. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocr Metab. 2009;23: 245-259.
3. Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev. 2001;22:75-110.
4. Tsagarakis S, Tsigos C, Vassiliou V, et al. Food-dependent androgen and cortisol secretion by a gastric-inhibitory polypeptide receptor activity expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: in vivo and in vitro studies. J Clin Endocrinol Metab. 2001; 86:583-589.
5. Reznik Y, Allali-Zerah V, Chayvialle JA, et al. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med. 1992;327:981-986.
6. Lebrethon MC, Avallet O, Reznik Y, et al. Food-dependent Cushing's syndrome: characterization and functional role of gastric inhibitor polyptide receptor i. The adrenal of three patients. J Clin Endocrinol Metab. 1998; 83:4514-4519.
7. Croughs RJ, Zelissen PM, van Vroonhoven TJ, et al. GIP-dependent adrenal Cushing's syndrome with incomplete suppression of ACTH. Clin Endocrinol(Oxf). 2000; 52:235-240.
8. Albiger NM, Occhi G, Mariniello B, et al. Food-dependent Cushing's syndrome: from molecular characterization to therapeutic results. Eur J Endocrinol. 2007;157:771-778.
9. Vassiliadi DA, Ntali G, Stratigou T, Adali M, Tsagarakis S. Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine. 2011;40:437-444.
10. Mazzuco TL, Chaffanjon P, Martinie M, Sturm N, Chabre O. Adrenal Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: prediction o. The efficacy of -blockade therapy and interest of unilateral adrenalectomy. Endocrine. 2009;56:867-877.
11. Lamas C, Alfaro JJ, Lucas T, Leccumberri B, Barcelo B, Estrada J. Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia Long-term follow-up of four cases. Eur J Endocrinol. 2002;146:237-240.
12. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47.
13. Preumont V, Mermrjo LM, Damoiseaux P, Lacroix A, Maiter D. Transient efficacy of octreotide and pasireotide (SOM 230) treatment in GIP-dependent Cushing's syndrome. Horm Metab Res. 2011;43:487-491.
14. Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome N Engl J Med. 1999;341:577-581.
15. Bovenberg SA, Pieters GF, Hofland LJ, Hermus AR. Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations. Neth J Med. 2004;62:456-458.
16. Lacroix A, Tremblay J, Rousseau G, Bouvier M, Hamet P. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med. 1997;337:1429-1434.
17. Mircescu H, Jilwan J, N'Diaye N, et al. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's syndrome J Clin Endocrinol Metab. 2000;85:3531-3536.
18. Daidoh H, Morita H, Hanafusa J, et al. In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin Endocrinol (Oxf). 1998;48:403-409.
19. Assie G, Louiset E, Sturm N, et al. Systematic analysis of G-protein coupled receptor expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab. 2010; 95:E253-262.